Biology Reference
In-Depth Information
longer half-life translates into less-frequent administration and may allow
greater patient compliance and satisfaction.
Conclusions
Patients in a PAD program sustain costs not only associated with collecting the
blood but also costs associated with its delivery (i.e., nursing care), with costs
estimated anywhere from US$400 to US$600 per patient. The use of erythro-
poietic factors such as epoetin alfa, epoetin beta, and darbepoetin alfa, have the
potential to increase important blood parameters such as hematocrit and
hemoglobin concentration safely and reliably while reducing the cost and need
for allogeneic blood transfusions in the orthopedic surgery setting.
References
1 Walker R (1987) Transfusion risks. Am J Clin Pathol 88: 371-378
2 Brunson ME, Alexander JW (1990) Mechanisms of transfusion-induced immunosuppression.
Transfusion 30: 651-658
3 Dodd RY (1992) The risk of transfusion-transmitted infection. N Engl J Med 327: 419-421
4 Goodnough LT, Skikne B, Brugnara C (2000) Erythropoietin, iron, and erythropoiesis. Blood 96:
823-833
5 Keating EM, Ritter MA (2002) Transfusion options in total joint arthroplasty. J Arthroplasty 17:
125-128
6 Cascinu S, Fedeli A, Del Ferro E, Luzi Fedeli S, Catalano G (1994) Recombinant human ery-
thropoietin treatment in cisplatin-associated anemia: A randomized double-blind trial with place-
bo. J Clin Oncol 12: 1058-1062
7 Ammann AJ, Cowan MJ, Wara DW, Weintrub P, D r itz S, Goldman H, Perkins HA (1983)
Acquired immunodeficiency in an infant: Possible transmission by means of blood products.
Lancet 1:956-958
8 Stevens CE, Aach RD, Hollinger FB, Mosley JW, Szmuness W, Kahn R, Werch J, Edwards V
(1984) Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis
in transfusion recipients: An analysis of the transfusion-transmitted viruses study. Ann Intern Med
101: 733-738
9 Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G (1989) Detection
of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and
chronic non-A, non-B hepatitis. N Engl J Med 321: 1494-1500
10 Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Vanssen RS, Lewis WF, Notari
EP 4 th , Petersen LR (1995) Estimated risk of transmission of the human immunodeficiency virus
by screened blood in the United States. N Engl J Med 333: 1721-1725
11 Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ (1996) The risk of transfusion-transmitted
viral infections. N Engl J Med 334: 1685-1690
12 Kleinman S, Busch MP, Schreiber GB (1997) The incidence/window period model and its use to
assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus
infection. Transfus Med Rev 11: 155-172
13 Alter HJ, Nakatsuji Y, M e lpolder J, Wages J, Wesley R, Shih JW, Kim JP (1997) The incidence of
transfusion-associated hepatitis G virus infection and its relation to liver disease. N Engl J Med
336: 747-754
14 Biggerstaff BJ, Petersen LR (2002) Estimated risk of West Nile virus transmission through blood
transfusion during an epidemic in Queens, New York City. Transfusion 42: 1019-1026
15 Houbiers JG, van de Velde CJ, van de Watering LM, Hermans J, Schreuder S, Bijnen AB,
Pahlplatz P, Schattenkerk ME, Wobbes T et al. (1997) Transfusion of red cells is associated with
Search WWH ::




Custom Search